Mackenzie Financial Corp Sells 99,604 Shares of AbbVie Inc. $ABBV

Key Points

• Mackenzie Financial Corp trimmed its AbbVie stake by 4.3% in Q3, selling 99,604 shares and leaving it with 2,238,097 shares valued at about $518.2 million.
• Notable insider selling occurred recently: EVP Perry C. Siatis sold 22,381 shares (~$5.15M) and SVP David Ryan Purdue sold 5,230 shares (~$1.22M), with corporate insiders owning roughly 0.08% of the company.
• AbbVie posted encouraging clinical wins—ABBV‑295 Phase 1 (≈7.8–9.8% mean weight loss at ~12 weeks) and positive Phase 3 AFFIRM SKYRIZI results—and analysts remain generally upbeat (average price target ≈$253.15), which could support the stock.

Mackenzie Financial Corp decreased its holdings in AbbVie Inc. (NYSE:ABBV - Free Report) by 4.3% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,238,097 shares of the company's stock after selling 99,604 shares during the period. Mackenzie Financial Corp owned about 0.13% of AbbVie worth $518,209,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Evolution Wealth Management Inc. bought a new position in shares of AbbVie in the second quarter worth about $26,000. Caitlin John LLC bought a new stake in AbbVie during the 3rd quarter valued at about $33,000. Financial Gravity Companies Inc. purchased a new stake in AbbVie in the 2nd quarter valued at about $36,000. Delos Wealth Advisors LLC purchased a new stake in AbbVie in the 2nd quarter valued at about $39,000. Finally, Redmont Wealth Advisors LLC bought a new position in AbbVie in the 3rd quarter worth about $41,000. 70.23% of the stock is currently owned by institutional investors.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie reported positive topline results from the Phase 1 multiple ascending dose study of ABBV-295 (long‑acting amylin analog) showing roughly 7.8–9.8% mean weight loss at ~12 weeks and a favorable tolerability profile — supports further development in chronic weight management and expands non‑incretin obesity options. AbbVie reports topline data from Phase I ABBV-295 trial
• Positive Sentiment: AbbVie announced positive Phase 3 AFFIRM results for SKYRIZI (risankizumab) subcutaneous induction in Crohn’s disease — a potential label/indication expansion that could extend revenue runway for an existing franchise. AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study
• Positive Sentiment: Industry coverage highlights ABBV‑295 and early obesity program data (up to ~10% weight loss) as a differentiator vs. incretin therapies — this boosts perception of AbbVie’s cardiometabolic pipeline optionality. AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study
• Positive Sentiment: J.P. Morgan reiterated its Buy stance on ABBV, an institutional vote of confidence that can support demand for the shares. J.P. Morgan Sticks to Its Buy Rating for AbbVie (ABBV)
• Neutral Sentiment: Citi’s Geoff Meacham maintained a Hold and $230 price target, signaling caution despite pipeline promise and limiting upside from analyst revisions. Neutral Hold on AbbVie as Early Cardiometabolic Pipeline Shows Promise but Trails Leading Competitors
• Neutral Sentiment: ResearchAndMarkets published an Elahere (mirvetuximab) market report outlining growth drivers in ovarian cancer — useful long‑term market context but not an immediate mover for ABBV shares. Elahere (AbbVie: mirvetuximab soravtansine-gynx) Market Research Report 2026
• Neutral Sentiment: AbbVie’s presentation/transcript at the Leerink Global Healthcare Conference provides management insight on growth drivers and pipeline prioritization — useful for modeling but not an immediate catalyst. AbbVie Inc. (ABBV) Presents at Leerink Global Healthcare Conference 2026 Transcript
• Negative Sentiment: ICER (cost‑effectiveness body) will review AbbVie’s Parkinson’s drug — an adverse assessment could limit pricing power/reimbursement and pressure long‑term revenue assumptions. ICER to review AbbVie’s Parkinson’s disease drug
• Negative Sentiment: Governance/headline risks: CEO Robert Michael received a sizable pay increase to $32.5M in year two, and an AbbVie SVP sold ~$1.22M in shares — both items can weigh on sentiment among governance‑focused investors. AbbVie's Robert Michael earns hefty pay bump to $32.5M in 2nd year as CEO AbbVie NYSE: ABBV SVP Sells $1,221,518.80 in Stock

Insider Buying and Selling

In other news, EVP Perry C. Siatis sold 22,381 shares of the company's stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the transaction, the executive vice president directly owned 38,137 shares of the company's stock, valued at approximately $8,771,510. This represents a 36.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the sale, the senior vice president owned 2,654 shares of the company's stock, valued at approximately $619,868.24. This represents a 66.34% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.08% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ABBV. Citigroup decreased their price target on shares of AbbVie from $235.00 to $230.00 and set a "neutral" rating for the company in a research note on Tuesday, January 27th. Morgan Stanley increased their price objective on AbbVie from $269.00 to $270.00 and gave the stock an "overweight" rating in a research note on Thursday, February 5th. Barclays assumed coverage on AbbVie in a research report on Thursday, February 19th. They set an "overweight" rating and a $275.00 target price for the company. Wall Street Zen upgraded AbbVie from a "buy" rating to a "strong-buy" rating in a report on Saturday, February 28th. Finally, Berenberg Bank set a $275.00 price target on AbbVie in a research report on Tuesday, January 20th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $253.15.

AbbVie Price Performance

Shares of ABBV stock opened at $226.68 on Wednesday. The stock's 50-day moving average is $224.60 and its 200 day moving average is $224.45. AbbVie Inc. has a 1-year low of $164.39 and a 1-year high of $244.81. The company has a market cap of $400.81 billion, a P/E ratio of 96.05, a PEG ratio of 0.79 and a beta of 0.34.

AbbVie (NYSE:ABBV - Get Free Report) last announced its earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping analysts' consensus estimates of $2.65 by $0.06. The business had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The firm's revenue was up 10.0% on a year-over-year basis. During the same period in the previous year, the company posted $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 3.1%. The ex-dividend date is Wednesday, April 15th. AbbVie's payout ratio is 293.22%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.